Mineral'naya plotnost' kosti i pokazatelikostnogo metabolizma u muzhchin s sindromomgiperprolaktinemii razlichnogo geneza
https://doi.org/10.14341/osteo2009114-18
Abstract
Hypogonadism is the most popular cause of BMD decreasing not only in women, but also in men. There are several studies showed a correlation between duration of hypogonadism and BMD reducing degree.
Despite wide light exposure of osteoporosis problem at women with hyperprolactinemia, there are a few researches devoted to the same question at men.
The aim of our study was to assess the biochemical parameters of bone metabolism and the bone mineral density (BMD) in men with tumoral and not tumoral hyperprolactinemia.
In 24 men with hyperprolactinemia and 17 healthy controls we evaluated BMD, serum osteocalcin (OK) and C-terminal telopeptide of type I collagen (CTX), as well as calcium total, ionized calcium and alkaline phosphatase. All men with hyperprolactinemia were also studied after 24 months of cabergoline treatment.
The results showed significant differences between study groups in BMD of vertebra and femur bone (p = 0,000052 up = 0,002718). We confirm increasing of BMD in vertebra and femur bone after cabergoline treatment (p = 0,003 и p = 0,027).
Despite wide light exposure of osteoporosis problem at women with hyperprolactinemia, there are a few researches devoted to the same question at men.
The aim of our study was to assess the biochemical parameters of bone metabolism and the bone mineral density (BMD) in men with tumoral and not tumoral hyperprolactinemia.
In 24 men with hyperprolactinemia and 17 healthy controls we evaluated BMD, serum osteocalcin (OK) and C-terminal telopeptide of type I collagen (CTX), as well as calcium total, ionized calcium and alkaline phosphatase. All men with hyperprolactinemia were also studied after 24 months of cabergoline treatment.
The results showed significant differences between study groups in BMD of vertebra and femur bone (p = 0,000052 up = 0,002718). We confirm increasing of BMD in vertebra and femur bone after cabergoline treatment (p = 0,003 и p = 0,027).
About the Authors
E. N. GiniyatullinaФГУ Эндокринологический научный центр
Russian Federation
L. Ya. Rozhinskaya
ФГУ Эндокринологический научный центр
Russian Federation
L. K. Dzeranova
ФГУ Эндокринологический научный центр
Russian Federation
N. G. Mokrysheva
ФГУ Эндокринологический научный центр
Russian Federation
N. I. Sazonova
ФГУ Эндокринологический научный центр
Russian Federation
G. S. Kolesnikova
ФГУ Эндокринологический научный центр
Russian Federation
A. D. Dobracheva
ФГУ Эндокринологический научный центр
Russian Federation
N. P. Goncharov
ФГУ Эндокринологический научный центр
Russian Federation
References
1. Беневоленская Л.И., Лесняк О.М. Клинические рекомендации. Остеопороз. М.: ГЭОТАР Медицина, 2005. 176 с.
2. Дзеранова Л.К. Диагностические и гормонально-метаболические аспекты гиперпролактинемии различного генеза. Автореф. дис. ... канд. мед. наук. М., 1993. 20 с.
3. Рожинская Л.Я., Марова Е.И., Дзеранова Л.К. и др. Состояние костной ткани у больных с гиперпролактинемическим гипогонадизмом. Проблемы эндокринологии. 1992; 38(6): 17-19.
4. Bordier P., de Seze S., Mravet L., Berbir N. Physiopathology of osteoporosis in the young adult. Sem Hop. 1974 Jan 14; 50(3): 197-206.
5. Charoenphandhu N., Limlomwongse L., Krishnamra N. Prolactin directly stimulates transcellular active calcium transport in the duodenum of female rats. Can J Physiol Pharmacol 2001 May; 79(5): 430-8.
6. Colao A., Di Sarno A., Marzullo P. Di Somma C., Cerbone G., Landi M.L., Faggiano A., Merola B., Lombardi G. New medical approaches in pituitary adenomas. Horm Res 2000; 53 Suppl 3: 76-87 40.
7. Colao A., Ferone D., Lastoria S. et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol. Oxford 2000 Mar, 52(3); 319-27.
8. De Vito W.J., Avakian C., Stone S., Okulicz W.C., Tang К. Prolactin induced expression of interleukin-1, tumor necrosis factor- in cultured astrocytes. J Cell Biochem 1995; 27: 290-298.
9. Di Somma C., Colao A., Di Sarno A., Klain M., Landi M.L., Facciolli G., Pivonello R., Panza N., Salvatore M., Lombardi G. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab. 1998 Mar; 83(3): 807-13.
10. Greenspan S.L., Neer R.M., Ridgway E.C., Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1986; 104: 77-82.
11. Greenspan S.L., Oppenheim D.S., Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1989; 110: 526 -531.
12. Jackson J.A., Kleerekoper M., Parfitt M. Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism. Ann Intern Med. 1986; 105: 543-545.
13. Kayath M.J., Lengyel A.M., Vieira J.G. Prevalence and magnitude of osteopenia in patients with prolactinoma. Brazil J Med Biol Res. 1993; 26: 933-941.
14. Klibanski A., Greenspan S.L. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1986 Aug 28; 315(9): 542-6.
15. Koppelman M.C.S., Kurtz D.W., Morrish K.A., et al. Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab. 1984; 59: 1050-1054.
16. Piyabhan P., Krishnamra N., Limlomwongse L. Changes in the regulation of calcium metabolism and bone calcium content during growth in the absence of endogenous prolactin and during hyperprolactinemia: a longitudinal study in male and female Wistar rats. Can J Physiol Pharmacol 2000 Oct; 78(10): 757-65.
17. Shaarawy M., El-Dawakhly A.S., Mosaad M., EI-Sadek M.M. Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Clin Chem Lab Med. 1999 Apr; 37(4): 433- 8.
18. Toning O., Isberg B., Sjoberg H.E., Bucht E., Hulting A.L. 1993 Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment. Acta Endocrinol (Copenh). 128: 423-427.
19. Vartej P., Poiana C., Vartej I. Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women.Gynecol Endocrinol. 2001 Feb; 15(1): 43-7.
20. Wasmch R.D., Ross P.D., Heilbrun L.K., Vogel J.M. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obset Gynecol. 1985; 153: 745-751.
Review
For citations:
Giniyatullina E.N., Rozhinskaya L.Ya., Dzeranova L.K., Mokrysheva N.G., Sazonova N.I., Kolesnikova G.S., Dobracheva A.D., Goncharov N.P. Mineral'naya plotnost' kosti i pokazatelikostnogo metabolizma u muzhchin s sindromomgiperprolaktinemii razlichnogo geneza. Osteoporosis and Bone Diseases. 2009;12(1):14-18. (In Russ.) https://doi.org/10.14341/osteo2009114-18
Views:
318
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
